US2017239254A1PendingUtilityA1
Deuterated derivatives of ruxolitinib
Assignee: CONCERT PHARMACEUTICALS INCPriority: Jun 15, 2012Filed: Mar 9, 2017Published: Aug 24, 2017
Est. expiryJun 15, 2032(~5.9 yrs left)· nominal 20-yr term from priority
A61P 35/00A61K 31/454A61K 31/4045A61K 31/7068A61K 45/06A61K 31/5685A61P 37/02A61K 31/519C07D 487/04C07B 2200/05A61P 35/02
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention in one embodiment provides a compound of Formula A: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising the compound; and methods of treating the indications disclosed herein.
Claims
exact text as granted — not AI-modified1 - 11 . (canceled)
12 . A method of inhibiting one or more of JAK1 and JAK2 in a cell, comprising contacting the cell with a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof.
13 . The method of claim 12 , wherein each position in the compound designated specifically as deuterium has at least 90% incorporation of deuterium, and wherein any atom not designated as deuterium is present at its natural isotopic abundance.
14 . The method of claim 12 , wherein each position in the compound designated specifically as deuterium has at least 95% incorporation of deuterium, and wherein any atom not designated as deuterium is present at its natural isotopic abundance.
15 . The method of claim 12 , wherein, the pharmaceutically acceptable salt of the compound is the phosphate salt.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.